Patient Preference Following Treatment with Dupilumab and Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: A Multicenter Retrospective Analysis

Name: Patient Preference Following Treatment with Dupilumab and Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: A Multicenter Retrospective Analysis
Creator: Nicole Baker
Published: 2026-10-12T16:49:07.687Z
Keywords: Biologicals, Atopic Dermatitis, Dermatitis, Eczema

Baker, Nicole; Alomary, Simona; Li, Andrew; Mastro, Andrew; Dasilva, Diego; Lewitt, G. Michael; Nguyen , Harrison; Song, E. James; Taylor, Susan; Murase, Jenny; Mollanazar, Nicholas

doi:10.17632/53drn7nkkc.2

Patient Preference Following Treatment with Dupilumab and Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: A Multicenter Retrospective Analysis

Published: 12 October 2026| Version 2 | DOI: 10.17632/53drn7nkkc.2

Contributors:

Nicole Baker, Simona Alomary,

, Andrew Mastro, Diego Dasilva, G. Michael Lewitt, Harrison Nguyen , E. James Song, Susan Taylor, Jenny Murase, Nicholas Mollanazar

Description

Supplemental Table 1: Summary of Patient Demographics including age, sex, length of trial on Dupilumab, length of trial on Lebrikizumab, history of asthma, and patients patch tested Supplemental Table 2: Outcomes after switching from Dupilumab to Lebrikizumab stratified by reason for switching from Dupilumab

Patient Preference Following Treatment with Dupilumab and Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: A Multicenter Retrospective Analysis

Description

Files

Categories

Licence